Overview

This is a foundational role in the expansion of the US Oncology marketing team for the hematology and solid tumor therapeutic areas. The Director will assume a key role responsible for a multitude of External Expert-related activities aimed at preparing the US commercial organization and the external marketplace for important launches and growth opportunities within a growing oncology organization. The individual who assumes this role will be responsible for executing all activitieswithin the Regional Marketing Oncology team to support ongoing product and potential launch activities.

Responsibilities

• Developing and executing the regional engagement plan for Stemline’s current and potential oncology/hematology products

• Leading or serving as a key commercial member on cross-functional initiatives, often with high visibility within the organization

• Effectively translating scientific, clinical, and market research into actionable commercial activities

• Leading the development and implementation of advisory boards across academic and community oncology HCPs and partnering w/medical affairs as appropriate

• Interacting effectively with opinion leaders and oncology medical associations

• Development and execution of the Regional Conference plan for regional Oncology meetings

• Building the strategic and operational readiness plans for speakers’ bureaus (nomination, training, content development, and monitoring)

• Aiding in the development of Peer to Peer and Speaker Program educational content, such as slide decks and patient cases

• Coordinating the development of regional integrated unbranded and branded tactics according to strategy and within agreed upon budgets

• Facilitating approval for marketing materials through internal review process to ensure marketing activities follow compliance with regulatory and legal requirements. Developing and implementing processes for accurate measurement and evaluation of effectiveness of activities

• Participating in the annual brand planning process, leading development of plans and budgets

• Cultivating relationships, managing, and providing direction and leadership to key agency partners to deliver on key strategic and tactical initiatives within timelines and allocated budget

• Collaborating with brand marketing teams to ensure alignment of key messages and customer insights

• Ability to carry out assigned tasks and work in a compliant manner

Qualifications

• 3 years of pharmaceutical marketing experience

• Launch experience in Oncology

• MBA or other advanced degree preferred

• Knowledge of the Breast Cancer Market and Opinion Leaders

• Strong interpersonal skills with the ability to interact with and present to OLs

• Excellent strategic thinking skills with ability to formulate, develop and execute strategy

• Ability to gather insights from customer engagements and translate market research findings into actionable insights and tactical plans

• Ability to understand and communicate clinical data and high-level science

• Strong capacity to collaborate with and lead cross-functional teams. Must work cooperatively with commercial management, clinical development, medical affairs, field sales leadership, regulatory, compliance, market research and others

• Demonstrated excellence in project management and effectively managing multiple projects/priorities

• Demonstrated ability to lead agencies and other external partners in aligning and developing tactical plans and promotional materials that are aligned with brand strategy

• Champion materials through medical, legal, regulatory reviews (promotional review process)

• Travel greater than 50% as dictated by business need, including overnights and attendance at some nighttime and weekend programs

Base Salary Range of $180,910 - $233,379. Menarini Stemline offers generous compensation and benefits packages, including Short and Long-Term Incentive Programs, Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.